JP2015513535A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513535A5
JP2015513535A5 JP2014558090A JP2014558090A JP2015513535A5 JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5 JP 2014558090 A JP2014558090 A JP 2014558090A JP 2014558090 A JP2014558090 A JP 2014558090A JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5
Authority
JP
Japan
Prior art keywords
inhibitor
phosphatidylserine
use according
receptor
tim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/053391 external-priority patent/WO2013124327A1/en
Publication of JP2015513535A publication Critical patent/JP2015513535A/ja
Publication of JP2015513535A5 publication Critical patent/JP2015513535A5/ja
Pending legal-status Critical Current

Links

JP2014558090A 2012-02-21 2013-02-20 ウイルス侵入補助因子としてのｔｉｍレセプター Pending JP2015513535A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305193 2012-02-21
EP12305193.0 2012-02-21
EP12306281.2 2012-10-17
EP12306281 2012-10-17
PCT/EP2013/053391 WO2013124327A1 (en) 2012-02-21 2013-02-20 Tim receptors as virus entry cofactors

Publications (2)

Publication Number Publication Date
JP2015513535A JP2015513535A (ja) 2015-05-14
JP2015513535A5 true JP2015513535A5 (https=) 2016-03-10

Family

ID=47739275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558090A Pending JP2015513535A (ja) 2012-02-21 2013-02-20 ウイルス侵入補助因子としてのｔｉｍレセプター

Country Status (7)

Country Link
US (1) US20160017035A1 (https=)
EP (1) EP2817327A1 (https=)
JP (1) JP2015513535A (https=)
BR (1) BR112014021068A8 (https=)
IN (1) IN2014DN07023A (https=)
MX (1) MX2014010016A (https=)
WO (1) WO2013124327A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817328A1 (en) 2012-02-21 2014-12-31 Institut National de la Santé et de la Recherche Médicale Tam receptors as virus entry cofactors
WO2014093627A2 (en) * 2012-12-13 2014-06-19 Children's Medical Center Corporation Compositions and methods for inhibiting viral entry
WO2015092035A1 (en) * 2013-12-20 2015-06-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Cd300a receptors as virus entry cofactors
US20170239329A1 (en) * 2014-10-15 2017-08-24 Annexin Pharmaceuticals Ab Therapeutic composition comprising annexin v
KR102582192B1 (ko) * 2014-12-05 2023-09-25 후지필름 가부시키가이샤 Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트
EP3464360B1 (en) 2016-05-27 2025-11-12 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
WO2019191406A1 (en) * 2018-03-29 2019-10-03 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric tim-3 fusion protein
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
CN119639892A (zh) * 2024-11-13 2025-03-18 浙江大学 一种分子标志物tim1及其在卵巢透明细胞癌中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
DE69727384T2 (de) 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
WO1999004819A1 (en) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
EP1071753A2 (en) 1998-04-20 2001-01-31 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
AU6815901A (en) 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002076428A1 (en) 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US20020192274A1 (en) 2001-03-26 2002-12-19 Ponnappa Biddanda C. pH sensitive liposomal drug delivery
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
JP2004535388A (ja) 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
DE10127526A1 (de) 2001-05-31 2002-12-12 Novosom Ag Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
DE10152145A1 (de) 2001-10-19 2003-05-22 Novosom Ag Stabilisierung von Liposomen und Emulsionen
US20030157030A1 (en) 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
AU2002359892A1 (en) 2001-12-31 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
WO2003066069A1 (en) 2002-02-01 2003-08-14 Intradigm Corporation Polymers for delivering peptides and small molecules in vivo
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
JP2005518470A (ja) 2002-02-22 2005-06-23 インサート セラピューティクス インコーポレイテッド 炭水化物−修飾ポリマー組成物及びその使用法
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
US20030198664A1 (en) 2002-03-29 2003-10-23 Sullivan Sean Michael Lipid mediated screening of drug candidates for identification of active compounds
DE60328383D1 (de) 2002-05-24 2009-08-27 Mirus Bio Corp Zusammensetzungen zur zuführung von nukleinsäuren an zellen
US7682626B2 (en) 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
JP2010530870A (ja) 2007-06-22 2010-09-16 エーテーツェー チューリッヒ 抗ウイルス剤
EP2219671A4 (en) * 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
EP2349321B1 (en) 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP2817328A1 (en) 2012-02-21 2014-12-31 Institut National de la Santé et de la Recherche Médicale Tam receptors as virus entry cofactors

Similar Documents

Publication Publication Date Title
JP2015513535A5 (https=)
WO2015042308A3 (en) Rna-based hiv inhibitors
Barcellini et al. Rituximab therapy for autoimmune haematological diseases
JP2014519662A5 (https=)
MX2019006411A (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos.
JP2012126742A5 (https=)
JP2018530530A5 (https=)
JP2015526391A5 (https=)
JP2014501492A5 (https=)
EP4632075A3 (en) Method for reducing immunogenicity of rna
JP2014513356A5 (https=)
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
JP2016513638A5 (https=)
JP2015521593A5 (https=)
JP2017070307A5 (https=)
JP2013539454A5 (https=)
WO2008014979A3 (en) NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
WO2013006795A3 (en) Antiviral compositions and methods of their use
JP2015518494A5 (https=)
BR112013002296A2 (pt) composição farmacêutica e respectivo uso e método para tratar doença infecciosa
JP2013503110A5 (https=)
CL2011001977A1 (es) Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades.
JP2014503593A5 (https=)